Accueil / Communiqués / CBPE Acquires Majority Investment in CRO Simbec-Orion

CBPE Acquires Majority Investment in CRO Simbec-Orion

Monday, February 4th 2019 at 10:51am UTC

LONDON–(BUSINESS WIRE)– Simbec-Orion Group Limited (“Simbec-Orion”), a leading European
full-service boutique clinical research organisation announced today
that CBPE Capital LLP (“CBPE”) has acquired a majority stake in the

The investment, made through a management buy-out, will provide funding
for further international growth and expansion by Simbec-Orion.

The investment made via the £459m CPBE Capital Fund IX, acquired the
shareholding of the Wales Life Sciences Investment Fund LP (“WLSIF”)
managed by Arix Capital Management Limited, a subsidiary of Arix
Bioscience PLC. The financial details of the transaction have not been

Simbec-Orion was formed by the merger of Simbec Research and Orion
Clinical in June 2014, funded by WLSIF having acquired Simbec Research
in May 2013.

Following several years of strong growth since 2014, Simbec-Orion has
seen total revenue increase from £13.2m for the period to December 2014
to an expected outturn in excess of £30m for the year ended 31 December

Simbec-Orion provides a broad, full service CRO offering to its clients
across all stages of development Phase I, II and III. Simbec-Orion
designs, executes and delivers its clients’ clinical development needs
across healthy volunteer and patient based clinical studies (including
project management, clinical operations, data management, statistics,
and regulatory affairs). In addition, Simbec-Orion offers a much broader
range of services than its peers with the full range of additional
clinical development services including central laboratory, IMP
management and pharmacovigilance.

Simbec-Orion (
focuses its breadth of resources on biotech companies and small-cap,
specialty and mid-cap pharmaceutical companies. The Group concentrates
on those in its areas of specialty particularly oncology, rare diseases
and orphan indications, respiratory conditions and translational
medicine (including FiH programmes).

CBPE’s investment will fund the continued growth of Simbec-Orion both
organically and through acquisitions. CBPE has a history of backing
experienced management teams with a track record in operational delivery
and M&A.

has committed additional funds for future investment in operations,
facilities and further expansion. The management team and CBPE intend to
pursue further expansion of the Group geographically, particularly in
the United States and Continental Europe, and across all its business

  • early stage healthy volunteer Phase I studies;
  • patient Phase I, II and III studies;
  • central laboratory; and
  • drug development consulting.

Professor Sir Christopher Evans, founder and Deputy Chairman of Arix
Bioscience PLC, said, “We first backed Simbec Research in May 2013
through the Wales Life Sciences Investment Fund. Today, the Group is in
strong financial health, the Welsh site employs more than 120 people and
the Group approximately 300 people. The investment announcement today is
excellent news for the company and for the Wales Life Sciences
Investment Fund’s commitment”.

Ronald Openshaw, Chief Executive Simbec-Orion said, “The combination
of Simbec Research and Orion Clinical provided the base to create a
growing CRO in the mid-market.
We created a strategy for a
clearly defined and differentiated offering where our people can use
their excellence, commitment and passion to improve patients lives.
are delighted to secure this return for the WLSIF and have clear plans
with CBPE for the future growth of the Group

Anand Jain, Partner CBPE, said “We have been following Simbec-Orion’s
growth since the merger in 2014 and are delighted to be supporting the
business through the next phase of its development. We are excited about
providing Simbec-Orion with the investment and support required to
further develop their services and to expand geographically


Tel: +44-175-357-8080


Ramsay Smith
Tel: +44-207-710-0020


Tel: +44-207-065-1100


Source: Simbec-Orion Group Limited

Voir aussi

Maverick Therapeutics to Unveil Pre-Clinical Data on Novel COBRATM Platform at American Association for Cancer Research 2019 Annual Meeting

Saturday, March 30th 2019 at 12:00pm UTC – Pre-clinical Data Characterize the Conditional and Potent …